Development of a Stereoselective Synthesis of (1 R ,4 R )- and (1 S ,4 S )-2-Oxa-5-azabicyclo[2.2.2]octane
Matthew L. Maddess,Ed Cleator,Mariko Morimoto,Adrian Goodyear,Alejandro Dieguez-Vazquez,Andrew Gibb,Andy Kirtley,Jie Wang,Ji Qi,Lingzhu Kong,Mahbub Alam,Stephen Keen,Steven F. Oliver,Xin Wen,Yu-Hong Lam
DOI: https://doi.org/10.1021/acs.oprd.1c00098
2021-06-07
Abstract:Despite the prevalence of morpholine derivatives and bridged heterocycles in medicinally relevant compounds, bridged bicyclic morpholines remain scarce because of the challenges associated with their synthesis. MRK A, an IDH1<sup>mut</sup> inhibitor for the treatment of glioma, derives its potency in part from substitution of a zigzag 2,5-bicyclic morpholine, 2-oxa-5-azabicyclo[2.2.2]octane, at C8. While existing entries suffered from low yields and lack of stereochemical control, we developed concise stereospecific routes toward both enantiomers of the zigzag morpholine antipode. The key common intermediate in the two routes was a chiral bicyclic lactone, which was readily synthesized following our previous synthesis of relebactam from optically pure (2<i>S</i>,5<i>S</i>)-5-hydroxypiperidine-2-carboxylic acid (HPA). The desired (<i>R</i>,<i>R</i>) enantiomer for incorporation into MRK A required inversion of both stereocenters of the bicyclic lactone intermediate, which was accomplished by epimerization via a crystallization-induced diastereomer transformation process followed by a key Ti(O<sup>i</sup>Pr)<sub>4</sub>-mediated intramolecular S<sub>N</sub>2 ring closure. By this method, the (<i>R</i>,<i>R</i>)-zigzag morpholine was synthesized in six steps from HPA in 25% overall yield.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.oprd.1c00098?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.oprd.1c00098</a>.Experimental details, characterization data, relevant computational data, NMR spectra and relevant supercritical fluid chromatography traces (<a class="ext-link" href="/doi/suppl/10.1021/acs.oprd.1c00098/suppl_file/op1c00098_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, organic, applied